Transformative Therapies for Depression: Postpartum Depression, Major Depressive Disorder, and Treatment-Resistant Depression
Annual Review of Medicine November 11, 2024 Elizabeth Richardson, Riah Patterson, Samantha Meltzer-Brody et al. 33 citations
Depressive disorders impose a heavy global public health burden, with a gap between how common they are and the availability of fast, effective treatments that lead to remission. Brexanolone and zuranolone, the first FDA-approved drugs for postpartum depression, mark a critical advance for a vulnerable patient group. Psilocybin shows promise for treatment-resistant depression and for people who have not found relief with existing options. This review discusses these transformative therapies as major steps forward for postpartum depression, major depressive disorder, and treatment-resistant depression.